Credit Suisse, Jefferies, Stifel, Wedbush PacGrow to assist with deal
By Devika Patel
Knoxville, Tenn., Aug. 12 – Celladon Corp. said it priced a $38 million public sale of stock with a $5.7 million greenshoe. The deal was announced July 30.
The company will sell 4 million common shares at $9.50 apiece. The price per share is a 7.68% discount to the Aug. 11 closing share price of $10.29.
Credit Suisse and Jefferies LLC are the joint bookrunning managers.
Settlement is expected Aug. 18.
Proceeds will be used for research and development, development of manufacturing capabilities, clinical development, general and administrative expenses and general corporate purposes.
The clinical-stage biotechnology company is based in San Diego.
| Issuer: | Celladon Corp
|
| Issue: | Common shares
|
| Amount: | $38 million
|
| Greenshoe: | $5.7 million
|
| Shares: | 4 million
|
| Price: | $9.50
|
| Warrants: | No
|
| Bookrunners: | Credit Suisse and Jefferies LLC
|
| Co-managers: | Stifel and Wedbush PacGrow Life Sciences
|
| Announcement date: | July 30
|
| Pricing date: | Aug. 12
|
| Settlement date: | Aug. 18
|
| Stock symbol: | Nasdaq: CLDN
|
| Stock price: | $10.29 at close Aug. 11
|
| Market capitalization: | $178.52 million
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
